Study in JAMA Network Open Examines Impact of Hepatitis Drug Price Reductions on Manufacturer and Health Care Organization Revenue
Pharmaceutical manufacturers rarely reduce drug list prices, but 3 expensive treatments for hepatitis C experienced significant list price reductions in 2018. Understanding the impetus for these price reductions could inform policies to reduce drug spending.